Article Text

PDF
Expansion of a mutated clone: from stem cell to tumour
  1. S J Leedham,
  2. N A Wright
  1. Histopathology Department, Cancer Research UK, London, UK
  1. Dr Simon J Leedham, Histopathology Department, Cancer Research UK, 44 Lincoln’s Inn Fields, London WC2A 3PX, UK; simon.leedham{at}cancer.org.uk

Abstract

Intestinal stem cells are adult, tissue-based stem cells located at the base of the intestinal crypt and are capable of regenerating all intestinal cell types. The progeny of mutated stem cells can expand to fill an entire crypt as a consequence of genetic drift, selective advantage or hitchhiking—eventually forming a clonal crypt population by a process called “niche succession”. Cancer is believed to be a disease of stem cells. The digestive tract has a very high cancer prevalence partly due to rapid epithelial cell turnover and exposure to dietary toxins. Work on the hereditary cancer syndromes, including familial adenomatous polyposis (FAP), has led to significant advances, including the adenoma–carcinoma sequence. The initial mutation involved in this stepwise progression is in the “gatekeeper” tumour suppressor gene adenomatous polyposis coli (APC). In FAP somatic, second hits in this gene are non-random events, selected for by the position of the germline mutation. The early growth of adenomas is contentious, with two main theories, the “top-down” and “bottom-up” hypotheses, attempting to explain the spread of dysplastic tissue in the bowel. Initial X chromosome inactivation studies suggested that colorectal tumours were monoclonal; however, work on a rare XO/XY human patient with FAP and chimeric Min mice showed that approximately 76% of adenomas were polyclonal. A reduction in tumour multiplicity in the chimeric mouse model has been achieved by the introduction of a homozygous tumour resistance allele. This model has been used to suggest that short-range interaction between adjacent initiated crypts, not random polyp collision, is responsible for tumour polyclonality.

Statistics from Altmetric.com

Footnotes

  • Funding: SL is a Medical Research Council Clinical Research Fellow.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.